In a sign that the tough climate for biotechs will last into 2023, Connect Biopharma cited the icy funding environment for its decision to halt a global phase 3 program for its lead dermatitis asset while it seeks out a suitable partner.

It’s back to the workshop for Blacksmith Medicines as it melds with originating company Forge Therapeutics to produce a metalloenzymes-focused biotech that will initially hammer out therapies for cancer and infections.

Pfizer’s gene therapy for severe hemophilia B has not only matched standard of care but beat it in a phase 3 study testing whether the treatment can help patients make the protein responsible for blood clotting on their own.

Hot on the heels of a major win for Apple in its patent dispute with fellow wearable device maker AliveCor, the tech giant has hit a roadblock.

A third patient death potentially tied to Eisai and Biogen’s Alzheimer’s disease drug lecanemab has been reported in a phase 3 extension study, according to a report from Science.

On the heels of hopeful clinical trial results for a drug that may work against Alzheimer’s, Japanese regulators have approved a simple blood test to identify potential patients with the hallmark signs of the disease.

Lexicon Pharmaceuticals has missed the mark in a phase 2 aiming to treat a common complication of shingles known as postherpetic neuralgia. However, the Texas biotech is standing by its therapy, saying the trial still demonstrates “clear evidence of effect.”

New details about David Sabatini’s ouster from MIT are coming to light after a leak of his former employer’s investigation into claims of abuse and misconduct.

Nearly two years after Philips first publicly raised concerns about the potential breakdown of the polyester-based polyurethane foam found in many of its CPAP and BiPAP machines and other respiratory devices, the company has wrapped up safety tests of some of its machines.

Zymeworks executives didn’t want to speak for Jazz Pharmaceuticals about the strength of data from a midstage readout for biliary tract cancer drug zanidatamab earlier this week. But it didn’t take long for Jazz to speak up loud and clear: We’re in.